用户48783635432019-04-09 14:29
【汇众医疗】Navidea宣布重启NAV3-31的2b期临床试验,此后股价上升13%
$Navidea生物制药(NAVB)$ Navidea根据FDA的反馈,宣布重启对NAV3-31的2b期临床试验计划,评估成像剂Tc99m tilmanocept在类风湿性关节炎患者中的应用。此举促进该公司股价上升了13%。 查看全文网页链接查看全文
艾萨克的猫2018-10-23 23:00
$Navidea Biopharmaceuticals, Inc. (NAVB)$ Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will pr...查看全文
$Navidea生物制药(NAVB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001437749-20-023028 Size: 15 KB 网页链接
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-20-023031 Size: 5 KB 网页链接
$Navidea生物制药(NAVB)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-002467 Act: 33 Size: 1 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, item 5.07 Accession Number: 0001437749-20-019570 Act: 34 Size: 43 KB 网页链接
$Navidea生物制药(NAVB)$ 内部交易: 2020-08-30,10% Owner,Scott John K Jr. ,买入,5000普通股, $5.00
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001753763-20-000002 Size: 8 KB 网页链接
$Navidea生物制药(NAVB)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-20-019241 Act: 33 Size: 564 KB 网页链接
$Navidea生物制药(NAVB)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-20-019242 Act: 33 Size: 527 KB 网页链接
$Navidea生物制药(NAVB)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-20-238219 Act: 34 Size: 49 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 1.01, 5.03, and 9.01 Accession Number: 0001437749-20-019237 Act: 34 Size: 448 KB 网页链接